International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 4 July-Aug 2024, pp: 730-737 www.ijprajournal.com ISSN: 2456-4494

A Review on Smoking Related Diffuse Cystic Lung Disease

K. Malleswari[1*], Dr.D. Rama Brahma Reddy[2], kandula Vijayalakshmi[3], Gorantla Avanthi Naga Deepthi Chowdary[4], Chavala Jeevitha[5]

[1*] *Associated professor, Department of Pharmaceutics, Nalanda Institute of Pharmaceutical Sciences, Sattenapalli(M), Guntur (Dt)-522 438, A.P, India.*

[2] *Principal &Professor, Department of Phytochemistry, Nalanda Institute of Pharmaceutical Sciences, Sattenapalli(M), Guntur (Dt)-522 438, A.P, India.*

[3,4,5] *Students, Department of Pharmacy, Nalanda Institute of Pharmaceutical Sciences, Sattenapalli(M), Guntur (Dt)-522 438, A.P, India.*

Date of Submission: 20-07-2024 Date of Acceptance: 30-07-2024

ABSTRACT:
The diffuse cystic lung diseases have a broad differential diagnosis. A wide variety of pathophysiological processes spanning the spectrum from airway obstruction to lung remodeling can lead to multifocal cyst development in the lung. Although lymphangioleiomyomatosis and pulmonary Langerhans cell histiocytosis are perhaps more frequently seen in the clinic, disorders such as Birt-Hogg-Dube syndrome, lymphocytic interstitial ´ pneumonia, follicular bronchiolitis, and light-chain deposition disease are increasingly being recognized. Obtaining an accurate diagnosis can be challenging, and management approaches are highly disease dependent. Unique imaging features, genetic tests, serum studies, and clinical features provide invaluable clues that help clinicians distinguish among the various etiologies, but biopsy is often required for definitive diagnosis. In part II of this review, we present an overview of the diffuse cystic lung diseases caused by lymphoproliferative disorders, genetic mutations**,** or aberrant lung development and provide an approach to aid in their diagnosis and management.

KEYWORDS: Birt-Hogg-Dube syndrome; Sjogren syndrome; ¨ high-resolution computed tomography; lymphoid interstitial pneumonia; follicular bronchiolitis.

I. INTRODUCTION:

Diffuse cystic lung diseases (DCLDs) are a heterogeneous group of pulmonary disorders that are characterized by multiple air-filled spaces, or cysts, within the lung parenchyma.1 Cysts are thin-walled (2 mm wall thickness), spherical, air-filled lucencies interfaced with normal lung tissue (Table 1).2 Critical review of cyst characteristics such as shape, size, wall thickness, and distribution on high-resolution computed tomography (HRCT) plays a major role in the evaluation of DCLDs. The exact mechanisms of cyst formation in DCLDs are not well elucidated and likely vary depending upon the underlying disease. Broadly, there are 3 major processes that have been linked to the development of cysts: (1) dilation of air spaces as a result of one-way obstruction in small airways leading to air entering but not exiting air spaces,3 (2) ischemia causing necrosis of small bronchioles,4 and (3) remodeling from matrix-degrading proteolytic enzymes.5 We have previously proposed a pathophysiology-based classification of DCLDs (Table 2). In this review, we will focus on the major DCLDs that a clinician is most likely to encounter in practice: lymphangioleiomyomatosis (LAM), pulmonary Langerhans cell histiocytosis (PLCH), Birt-Hogg-Dube´ syndrome (BHD), and lymphoid interstitial pneumonia (LIP)/follicular bronchiolitis (FB)[2]

TYPES:
DISEASES:
1.Lymphangioleiomyomatosis
2.Pulmonary Langerhans Cell Histiocytosis
3.Brit-Hogg-Dube Syndrome
4.Lymphoid Interstitial Pneumonia
5.Light Chain Deposition Disease

INFECTIONS:
1.Pneumocytosis
2. Infection with Staphylococcus aureus
3. Paracoccidioidomycosis

DISEASES

1. LYMPHANGIOLEIOMYOMATOSIS:

Lymphangioleiomyomatosis (LAM) is a rare DCLD that predominantly affects women.6 The average age at diagnosis is 35 y,1 but it has

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 4 July-Aug 2024, pp: 730-737 www.ijprajournal.com ISSN: 2456-4494

been reported in all age groups ranging from teenagers to elderly females.7,8 LAM occurs in 2 forms: in patients with the inheritable disease tuberous sclerosis complex (TSC-LAM), and in a sporadic form in patients without TSC.9 The estimated prevalence of LAM is 5–8 per million women,10 although that is almost certainly an underestimate.[3]



FIGURE 1: Lymphangioleiomyomatosis

TREATMNT:

- M TOR inhibitors, to regulate the growth of LAM cells
- Bronchodilators, to help improve breathing
- Oxygen therapy(11)

2. PULMONARY LANGERHANS CELL HISTIOCYTOSIS:

Pulmonary LCH is a smoking-related lung disease, with 80–100% of cases seen in patients who smoke or have a history of smoking. LCH occurs most frequently in young adults. Peribronchiolar infiltration of Langerhans and inflammatory cells results in bronchiolo-centric stellate interstitial nodules.The nodules may subsequently cavitate and form thick- and thin-walled cysts thought to represent enlarged airway lumina. Frequently, both nodules and cysts are seen. Cysts may be round but are often irregular, bilobed, cloverleaf-shaped, or bizarre shapes. Irregular cysts, cysts with nodules, and upper zone predominance with sparing of the costophrenic angles are features that distinguish(LCH) from Lymphangioleiomyomatosis.[3]



Figure-02: Pulmonary Langerhans Cell Histiocytosis

TREATMENT:

- A person with PLCH should try to quit smoking. This can result in complete remission.
- Other than quitting smoking, research suggests that there is no effective treatment.(11)

3. BIRT-HOGG-DUBE SYNDROME:

This rare disease has an autosomal dominant inheritance pattern and involves multiple areas of the body, including hair follicle tumors, renal neoplasm, and pulmonary cysts. BHD syndrome is seen in patients in their fourth and fifth decades of life, without a difference in males versus females. Pneumothorax is (typically) recurrent in 75% of BHD syndrome patients. As noted above, thepathogenesis of the disease is a genetic mutation of FLCN, leading to a mTOR signaling abnormality, although whether this mutation causes the activation or inactivation of mTOR is unclear. Another potential pathway is via the abnormal expression of TGF-β or neoplasia (differentially expressed in normal and neoplastic cells [DENN]) protein. FLCN is located on chromosome 17p, and

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 4 July-Aug 2024, pp: 730-737 www.ijprajournal.com ISSN: 2456-4494

> 140 FLCN DNA mutations have been identified to date.[4]



FIGURE-3:BIRT-HOGG-DUBE SYNDROME

TREATMENT:
To treat the cysts, a healthcare professional may recommend a blebectomy or a bullectomy.
These are surgical procedures to remove the cysts. (11)

4. LYMPHOID INTERSTITIAL PNEUMONIA:

Lymphocytic interstitial pneumonia (LIP) is a clinicopathologic term that describes diffuse involvement of lung parenchyma by reactive pulmonary lymphoid tissue. Follicular bronchiolitis (FB) refers to a pattern of lymphoid follicular hyperplasia centered on airways, vessels, and interlobular septa consistent with a lymphatic distribution. FB and LIP can be idiopathic or associated with a variety of underlying conditions, most commonly autoimmune disorders like Sjögren syndrome (SS), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), or immunodeficiency states such as HIV and common variable immune deficiency.(SS) is a chronic inflammatory autoimmune exocrinopathy that can occur in isolation (primary SS) or in combination with other rheumatologic conditions, such as rheumatoid arthritis, SLE, and systemic sclerosis (secondary SS). Among the connective tissue disorders, SS is most commonly associated with LIP/FB.[5]



Figure-04: Lymphoid Interstitial Pneumonia

TREATMENT:
- Treatment varies depending on the underlying cause of the LIP.(11)

5. LIGHT CHAIN DEPOSITION DISEASE:

Light-chain deposition disease (LCDD) is a rare disease that is characterized by deposition of a non-fibrillary amorphous material in alveolar walls and small airways. Contrary to amyloidosis, this acellular material does not have β-pleated sheet configuration and therefore does not bind Congo red stainIn rare instances, LCDD can have isolated pulmonary involvement; however, LCDD is usually associated with multiple myeloma and other lymphoproliferative disorders, and renal involvement resulting in proteinuria is common among patients.LCDD lung cysts vary in size and shape and could resemble LAM or PLCH on chest radiography.LCDD is usually a progressive disorder that results in respiratory failure.

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 4 July-Aug 2024, pp: 730-737 www.ijprajournal.com ISSN: 2456-4494

Treatment involves treating the underlying lymphoproliferative disorder (if present), with lung transplantation being an option for advanced cases.[6]



Figure-05: Light Chain Deposition Disease

INFECTIONS

1. PNEUMOCYTOSIS:

Pneumocystosis, which is caused by the fungus Pneumocystis jiroveci, occurs in immunocompromised patients, such as HIV-infected patients with CD4 lymphocyte counts below 200 cells/mm^3, bone marrow transplant recipients, and patients on immunosuppressants. Symptoms, such as nonproductive cough, low fever, and dyspnea, are insidious, and spontaneous pneumothorax can occur-if left untreated, patients can progress to respiratory failure and death. Lymphopenia and high serum levels of lactate dehydrogenase aid in the diagnosis.

CT findings include extensive areas of ground-glass opacity, preferentially located in the central and perihilar regions; septal thickening; and, possibly, pleural effusion and lymph node enlargement. Intralobular septal thickening associated with ground-glass opacities can result in a "crazy-paving" pattern. Cysts are relatively common, especially in HIV-infected patients, varying in size, shape, and wall thickness and tending to have a predilection for the upper lobes . Cyst rupture can cause pneumothorax and pneumomediastinum.[7]



Figure-06: Pneumocystosis

2. INFECTION WITH STAPHYLOCOCCCUS AUREUS:

Staphylococcal pneumonias can lead to the formation of pneumatoceles, which consist of gaseous airspaces resulting from airway dilatation due to a check-valve mechanism and occurring secondary to inflammation and parenchymal necrosis.[1] Pneumatoceles are most common in patients under one year of age and in intravenous drug users, and lesions can resolve with treatment of the infection.[7]

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 4 July-Aug 2024, pp: 730-737 www.ijprajournal.com ISSN: 2456-4494



Figure- 07: Infection with staphylococcus aureus

3. PARACOCCIDIOMYCOSIS:

Paracoccidioidomycosis, which is caused by the dimorphic fungus Paracoccidioides brasiliensis, is the most common systemic mycosis in Latin America. It predominates in males and in rural workers. Paracoccidioidomycosis is acquired by inhalation of infectious fungal particles that, upon reaching the lungs, cause the primary infection. Mucocutaneous lesions and lymph node enlargement are also common findings, and other less commonly affected organs include the kidneys, liver, bones, adrenal glands, central nervous system, and airways, with the formation of epithelioid granulomas, abscesses, and necrosis.[21]Several radiological patterns have been described, including reticular opacities, consolidations, areas of "reversed halo" sign, bronchiectasis, pulmonary cavitations, and paracicatricial emphysema.[22] In a CT review of 50 cases,[4] lung cysts were found in 10% of cases, and, in most cases, the cysts were diffuse and thin-walled, showing no preferential distribution, and few in number. Postulated mechanisms of cyst formation include bronchial obstruction caused by centrilobular fibrosis, peribronchial granuloma formation leading to airway dilatation or central necrosis and lesion elastic recoil.[7]



Figure-08: Paracoccidiomycosis

ETIOLOGY:

In our LAM clinic, most subjects (711/1010, 70.4%) were diagnosed with LAM. Among them, the number of individuals with definite and probable LAM was 646 and 65, respectively. Most of the cases were sporadic LAM, and 58 were tuberous sclerosis (TSC)-associated LAM. Pathological results were obtained in 38.1% of LAM patients. The remaining 65 cases were probable LAM, 47 of them have serum vascular endothelial growth factor-D (VEGF-D) tested and within normal ranges.

The number of SS patients was 38. Two patients were diagnosed with light-chain deposition disease (LCDD) and 2 patients were diagnosed with amyloidosis by video-assisted thoracic surgery (VATS) or transbronchial lung biopsy (TBLB). One patient was diagnosed with lymphocytic interstitial pneumonia (LIP) by VATS. There were 46 patients diagnosed with BHD, all of whom had folliculin (FLCN) gene mutations. Fourteen patients were diagnosed with PLCH. These PLCH patients underwent VATS lung biopsy or TBLB, and the sample showed Langerhans cells. Three patients had lung tumors, and their pathology results were lung adenocarcinoma (1 patient), lymphangioma (1 patient), and unclassified spindle cell tumors (1 patient). Two patients had Castleman disease based on lung biopsy, clinical manifestations, and laboratory tests. Two patients were diagnosed with antineutrophil cytoplasmic antibody-associated vasculitis based on manifestations, lung CT findings, and positive for anti-neutrophil cytoplasmic antibody (ANCA). One patient had

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 4 July-Aug 2024, pp: 730-737 www.ijprajournal.com ISSN: 2456-4494

Marfan syndrome based on typical clinical features and a family history of Marfan syndrome and a mutation of FBN1. One patient was diagnosed with systemic lupus erythematosus based on multisystemic involvement and positivity of anti-double-stranded DNA. One patient with amyloidosis, one patient with congenital cystic adenomatoid malformation of the lung, and one patient with pleuro parenchymal fibroelastosis were diagnosed by lung biopsy. For the other 189 patients, a definite diagnosis could not be made after several examinations. The distribution of etiologies is shownTable . The top four causes of DCLD were LAM, BHD, SS, and PLCH, accounting for 80.1% of the causes of DCLD. There were 18.7% of patients undiagnosed.[8]

Table-01: Etiology of Diffuse Cystic Lung Diseases

	Numbers	Age (years)	Female (%)	Smoking history
LAM	711	38.2 ± 10.8	711(100.0%)	1.1%
BHD	46	47.3 ± 10.4	42 (91.3%)	6.5%
SS	38	49.7 ± 10.4	38 (100.0%)	2.6%
PLCH	14	32.8 ± 12.4	6 (42.9%)	92.9%
Tumor	3	41–50	3 (100.0%)	0
CD	2	34–46	1 (50%)	50%
AVA	2	37–51	2 (100%)	0
SLE	1	45	1 (100%)	0
MFS	1	57	0	0
AMY	1	32	1 (100.0%)	0
CCAM	1	28	1 (100.0%)	0
PPFE	1	37	1 (100.0%)	0

EPIDOMOLOGY:

[9]This direct causative role for smoking in the pathogenesis of these disorders is based on significant epidemiological data:

- Consistent preponderance of smokers with in this population.
- Potential of this is remission upon smoking cessation.
- Existence of similar lesions, respiratory bronchiolitis, in healthy smokers without ILD (Interstitial Lung Disease)
- The presence of a combination of these lesions in some effected smokers.
- Cysts are rare in asymptomatic individuals <55 years of age but their prevalence increases with age.
- Cystic lung diseases mostly affect in women between ages 20-40.

PATHOPHYSIOLOGY:



Figure-09: Pathophysiology of Smoking Related Diffuse Cystic Lung Disease

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 4 July-Aug 2024, pp: 730-737 www.ijprajournal.com ISSN: 2456-4494

Inhaled cigarette smoke and other irritants activate epithelial cells and macrophages to release chemotactic factors that attract inflammatory cells to the lungs, including CCL2, which acts on CCR2 to attract monocytes, CXC-chemokine ligand (CXCL)1 and CXCL8, which act on CCR2 to attract neutrophils and monocytes (which differentiate into macrophages in the lungs) and CXCL9, CXCL10 and CXCL11, which act on CXCR3 to attract Th1 cells (T cell helper) and type 1 cytotoxic T-cells (Tc1 cells). These cells, together with macrophages and epithelial cells, release proteases, such as matrix metalloproteinase (MMP)9, which cause elastin degradation and emphysema. Neutrophil elastase also causes mucus hypersecretion. Epithelial cells and macrophages release transforming growth factor (TGF)-β, which stimulates fibroblast proliferation, resulting in fibrosis in the small airways.T helper type 1 (Th1) cells are a lineage of $CD4^+$ effector T cell that promotes cell-mediated immune responses and is required for host defense against intracellular viral and bacterial pathogens. Th1 cells secrete IFN-gamma, IL-2, IL-10, and TNF-alpha/beta.
Pigmented "smoker's macrophages" in respiratory bronchioles and neighbouring alveoli, containing granular, yellow-brown cytoplasmic pigments.[10]

SIGNS & SYMPTOMS:

- Fatigue
- Weight loss
- Exertional dyspnea
- Non-productive cough
- Wheezing
- Recurrent pneumonia
- Discomfort in the chest
- Extreme tiredness and weakness

DIAGNOSIS:

The diagnostic criteria of LAM were initially based on the guidelines of the European Respiratory Society (ERS) in 2010 and updated according to the 2017 guidelines by the American Toracic Society and Japanese Respiratory Society (ATS/JRS). All defnite LAM cases were reviewed and diagnosed based on the 2017 guidelines. Probable LAM was diagnosed based on the criteria of the 2010 guidelines, without other supporting evidence. The diagnoses of Sjogren's syndrome (SS) , Birt–Hogg– Dubé syndrome (BHD) , pulmonary Langerhans cell histiocytosis (PLCH) , systemic lupus erythematosus , Castleman's disease , antineutrophil cytoplasmic antibody-associated vasculitis , and Marfan syndrome were based on published criteria. Amyloidosis , light-chain deposition disease (LCDD), congenital cystic adenomatoid malformation of the lung, pleuroparenchymal fbroelastosis,and lung tumor were diagnosed based on pathology.[10]

II. CONCLUSION:

DCLD on chest imaging carries a broad differential diagnosis and can occur as a result of multiple pathophysiologically distinct disease processes. The presence of cysts in the pulmonary parenchyma creates unique physiological and clinical implications for respiratory providers, including respiratory therapists (Table 6). Establishing the correct diagnosis is crucial because DCLDs vary widely in clinical course, prognosis and treatment. Chest HRCT remains the most important noninvasive tool for evaluation of DCLDs. Careful and systematic evaluation of the cyst characteristics on HRCT, integrated with clinical, laboratory, and histopathology (if available) features can help narrow the field and guide the clinician toward the right path in the diagnosis and management of these patients.

REFERENCE:

[1]. Nishant Gupta1,2, Robert Vassallo3, Kathryn A. WikenheiseBrokamp4,5,6, and Francis X. McCormack1,2,Diffuse Cystic Lung Disease Part II,CONCISE CLINICAL REVIEW,2015,192,(1),17-29.
[2]. Baha Obaidat, Dina Yazdani, Kathryn A Wikenheiser-Brokamp, and Nishant Gupta,Diffuse Cystic Lung Diseases,2020;65(1):111–126.
[3]. Danielle M.Semen,Cristopher, A. Meyer, Mattew, D.Gilman,and Franics X.MC Cormack,Diffuse cystic lung disease at high-resolution CT,American journal of Roentgenology,2011,196(6)135-142.
[4]. Sanghoon Park1 and Eun Joo Lee2,Diagnosis and treatment of cystic lung disease,Korean J Intern Med 2017;32(2):229-238.
[5]. Nishant,Gupta,Robert Vassallo,Leathryn.A;Wikenheiser,Brokam pFrancis-X,MC Cormack,Diffuse cystic lung disease part- II, American journal of Respiratory and Critical Care Medicine,2015,192(1);387-396.
[6]. Baha Obaidat,Dina Yazdani,Kathryn.A,Wikencheiser,Brokam p and Nishant Gupta,Diffuse Cystic Lung

Disease,Respiratory Care,2020,65(1),111-126.

[7]. Han Cui, Chongsheng Cheng, Kai-Feng XU, The Etiology of diffuse cystic lung diseases, Orphanet Journal of rare diseases, 2021,64(2)273-279.

[8]. Sanghoon Parlk,Eun Joo Lee, Diagnosis and Treatment of Cystic lung disease, The Korean Journal of Internal Medicine, 2017, 32(2):229-238.

[9]. Barnes p, Smoking Cigarettes Pathophysiology, Respiratory Medicine,2004,98(2):139-151.

[10]. Han Cui1,2, Chongsheng Cheng1, Wenshuai Xu1, Xinlun Tian1, Yanli Yang1, Yani Wang1, Jiannan Huang1, Yudi He1, Jun Wang1, Ruie Feng, Weihong Zhang4 and Kai-Feng Xu1,The etiology of difuse cystic lung diseases: an analysis of 1010 consecutive cases in a LAM clinic,Cui et al. Orphanet J Rare Dis (2021) 16:273-279.

[11]. Hana Ames, what to know about lung cysts, Medical News Today,2023,32(1):124-130.

[12]. Baha Obaidat, Dina Yazdani, Kathryn A Wikenheiser-Brokamp, and Nishant Gupta,Diffuse Cystic Lung Diseases,2020;65(1):111–126.